Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System

NCT ID: NCT05805137

Last Updated: 2025-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-20

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the functionality of a new type of wound monitoring method and measurement system for monitoring healing of venous ulcers. The system is consisted of a wound dressing with electrodes (eDressing), a bioimpedance measurement device and a mobile phone application.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The technical principle of the monitoring method is based on the quasimonopolar bioimpedance measurement. The measurement system consists of a bioimpedance measuring device, a wound dressing with electrodes (eDressing) and a mobile application for use with a mobile phone.

The electrode dressing is placed on top of a wound, in contact with the wound tissue. The other necessary dressing layers (such as absorbent dressings and compression bandages) are placed over the electrode dressing. The electrode dressing is kept on the wound for maximum of seven consecutive days. The electrode dressing can be removed and replaced when needed due to medical reasons. Other dressings can be changed considered necessary.

During a study subject visit, the bioimpedance measurement is made using the device, the uppermost dressings are opened carefully and it is ensured that the wound condition is as expected. Upon the replacement of the electrode dressing, the wound is photographed and documented. The wound area is measured, and the findings are recorded.

A maximum of 20 subjects with venous ulcers will be recruited for the study in two study sites (Gdansk, Poland and Tampere, Finland).

Adult subjects (≥18 years) with venous ulcer who are applicable for compression therapy treatment, whose ulcer is not wider than 5 cm and does not excrete excessively can be recruited to the study. Previous surgical venous procedure is not an exclusion criterion for enrollment, but surgical procedure can not be performed during the study.

A subject shall visit the clinic 2-3 times a week, according to the doctor's or study nurse's assessment. Wound healing is monitored until the wound re-epithelized (\>90% of initial wound surface area) or maximum two months. Thus, there will be a maximum of 24 study visits per subject.

In addition to scientific objectives, the results of this study are also used as part of clinical evidence when submitting the technical documentation to Notified Body for assessment of the conformity of the device before being placed on the market.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study subject with venous ulcer

The subjects will be monitored using the WoundWatch wound management system two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.

Group Type EXPERIMENTAL

WoundWatch® wound monitoring system

Intervention Type DEVICE

eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WoundWatch® wound monitoring system

eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bioimpedance measurement of wound healing

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age at least 18 years
* The subject has a chronic lower extremity ulcer with a primary etiology of venous insufficiency. The previous venous procedure is not an obstacle to the study
* Compression therapy can be implemented
* The wound is not wider than 5 cm and the electrode dressing can be placed on the wound as intended. The wound should be located above the ankle, on the skin area where the electrode dressing can be placed properly.
* The wound is not deep with steep edges or cavity-like
* The wound is not highly excreting
* The wound can be expected to heal within two months (area reduced ≥ 90% from baseline)
* The subject gives consent to the study and commits to following the instructions of the medical staff

Exclusion Criteria

* Clinical wound infection at the time of the study
* The subject has an intravenous (in Tampere: A venous operation) procedure within 2 months
* Significant arterial circulatory disorder or adherence problem that prevents compression therapy (in Tampere: Contraindication for compression therapy, e.g. significant arterial circulatory disorder or severe heart failure)
* Subject movement 2-3 times a week during the study to the study site is difficult to arrange (in Tampere: Subject not able to commit to study visits 2-3 times a week.)
* Diagnosed epoxy resin allergy
* Any other reasons of potential study subject non-compliance by the opinion of the investigator


* Special groups, such as pregnant women/patients trying to conceive during the study or patients with reduced autonomy
* Subject with any implantable electrical device. Such as pacemaker or implanted defibrillator. Patient has other electrically conductive implanted material in legs. Such as a metallic prostheses.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Clinical Centre, Gdansk

OTHER

Sponsor Role collaborator

Medical University of Gdansk

OTHER

Sponsor Role collaborator

Tampere University Hospital

OTHER

Sponsor Role collaborator

CutoSense Oy

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Piotr Spychalski, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

TAYS Haavakeskuksen poliklinikka

Tampere, , Finland

Site Status RECRUITING

University Clinical Centre, Gdańsk

Gdansk, , Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Finland Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Atte Kekonen, M.Sc.

Role: CONTACT

+358407273627

Tuomas Lunden, B.Sc.

Role: CONTACT

+358407211679

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tiina Ahti, MD, Ph.D.

Role: primary

+358 45 7396 5952

Atte Kekonen, M.Sc.

Role: backup

+40 727 3627

Magdalena Antoszewska, MD

Role: primary

+48698748705

Piotr Spychalski, MD, Ph.D.

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Kekonen A, Bergelin M, Eriksson JE, Vaalasti A, Ylanen H, Kielosto S, Viik J. Bioimpedance method for monitoring venous ulcers: Clinical proof-of-concept study. Biosens Bioelectron. 2021 Apr 15;178:112974. doi: 10.1016/j.bios.2021.112974. Epub 2021 Jan 7.

Reference Type BACKGROUND
PMID: 33524705 (View on PubMed)

Kekonen A, Bergelin M, Johansson M, Kumar Joon N, Bobacka J, Viik J. Bioimpedance Sensor Array for Long-Term Monitoring of Wound Healing from Beneath the Primary Dressings and Controlled Formation of H2O2 Using Low-Intensity Direct Current. Sensors (Basel). 2019 May 31;19(11):2505. doi: 10.3390/s19112505.

Reference Type BACKGROUND
PMID: 31159298 (View on PubMed)

Kekonen A, Bergelin M, Eriksson JE, Vaalasti A, Ylanen H, Viik J. Bioimpedance measurement based evaluation of wound healing. Physiol Meas. 2017 Jun 22;38(7):1373-1383. doi: 10.1088/1361-6579/aa63d6.

Reference Type BACKGROUND
PMID: 28248191 (View on PubMed)

Antoszewska M, Spychalski P, Kekonen A, Viik J, Baranska-Rybak W. Bioimpedance sensor array for monitoring chronic wounds: Validation of method feasibility. Int Wound J. 2024 Aug;21(8):e14899. doi: 10.1111/iwj.14899.

Reference Type BACKGROUND
PMID: 39099180 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://cutosense.fi/

CutoSense Oy homepage (Sponsor)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R23094L (WW001 TAYS)

Identifier Type: REGISTRY

Identifier Source: secondary_id

WW001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.